The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Dec. 27, 2021
Applicant:

Jiangnan University, Wuxi, CN;

Inventors:

Gang Wang, Wuxi, CN;

Wei Chen, Wuxi, CN;

Jianxin Zhao, Wuxi, CN;

Hao Zhang, Wuxi, CN;

Xi Liang, Wuxi, CN;

Qingmin Kong, Wuxi, CN;

Qixiao Zhai, Wuxi, CN;

Wenwei Lu, Wuxi, CN;

Shumao Cui, Wuxi, CN;

Bo Yang, Wuxi, CN;

Bingyong Mao, Wuxi, CN;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/747 (2015.01); A23L 33/135 (2016.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01);
U.S. Cl.
CPC ...
A61K 35/747 (2013.01); A23L 33/135 (2016.08); C12N 1/20 (2013.01); C12R 2001/225 (2021.05);
Abstract

The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms.CCFM1051,CCFM1052 andCCFM1053 of the present disclosure have high adsorption effect on PFOA, can significantly relieve liver oxidative stress damage and serum biochemical indicators caused by PFOA, spleen atrophy caused by PFOA exposure, imbalance of intestinal microorganisms caused by PFOA exposure and metabolic disorder of intestinal flora caused by PFOA exposure, significantly increase the content of acetic acid and propionic acid in the intestinal tract, increase the fecal water content and decrease first black stool defecation time of mice with constipation, improve proliferation and MafA gene expression of INS-1 cells under high glucose, have the potential to relieve PFOA-related diabetes, reduce occurrence of liver diseases, metabolic diseases and potential carcinogenicity, and have broad use prospects.


Find Patent Forward Citations

Loading…